CN105814065B - 用作tnf活性调节剂的咪唑并噻唑衍生物 - Google Patents

用作tnf活性调节剂的咪唑并噻唑衍生物 Download PDF

Info

Publication number
CN105814065B
CN105814065B CN201480067061.8A CN201480067061A CN105814065B CN 105814065 B CN105814065 B CN 105814065B CN 201480067061 A CN201480067061 A CN 201480067061A CN 105814065 B CN105814065 B CN 105814065B
Authority
CN
China
Prior art keywords
alkyl
methyl
optionally substituted
heteroaryl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480067061.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105814065A (zh
Inventor
R·P·亚历山大
M·H·阿利
J·A·布朗
V·E·杰克逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of CN105814065A publication Critical patent/CN105814065A/zh
Application granted granted Critical
Publication of CN105814065B publication Critical patent/CN105814065B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201480067061.8A 2013-12-09 2014-12-08 用作tnf活性调节剂的咪唑并噻唑衍生物 Expired - Fee Related CN105814065B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1321731.0A GB201321731D0 (en) 2013-12-09 2013-12-09 Therapeutic agents
GB1321731.0 2013-12-09
PCT/EP2014/076842 WO2015086504A1 (en) 2013-12-09 2014-12-08 Imidazothiazole derivatives as modulators of tnf activity

Publications (2)

Publication Number Publication Date
CN105814065A CN105814065A (zh) 2016-07-27
CN105814065B true CN105814065B (zh) 2018-11-23

Family

ID=50000414

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480067061.8A Expired - Fee Related CN105814065B (zh) 2013-12-09 2014-12-08 用作tnf活性调节剂的咪唑并噻唑衍生物

Country Status (11)

Country Link
US (1) US10273247B2 (https=)
EP (1) EP3080133B1 (https=)
JP (1) JP6483700B2 (https=)
CN (1) CN105814065B (https=)
BR (1) BR112016011522B1 (https=)
CA (1) CA2930912C (https=)
ES (1) ES2743190T3 (https=)
GB (1) GB201321731D0 (https=)
RU (1) RU2683940C1 (https=)
TR (1) TR201910983T4 (https=)
WO (1) WO2015086504A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
EP3288939A1 (en) 2015-04-17 2018-03-07 AbbVie Inc. Tricyclic modulators of tnf signaling
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CA3072989A1 (en) * 2017-08-17 2019-02-21 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2022100727A1 (zh) * 2020-11-16 2022-05-19 广州市恒诺康医药科技有限公司 咪唑并噻唑类化合物、其药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
CN1823072A (zh) * 2003-05-15 2006-08-23 艾科尔公司 作为p38抑制剂的咪唑并噻唑和咪唑并噁唑衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463212A1 (en) * 1990-06-27 1992-01-02 Nikken Chemicals Co., Ltd. Imidazo[2,1-b]thiazole compound anti-ulcer agent containing the same
US5577987A (en) 1994-07-07 1996-11-26 Precise Exercise Equipment Co. Abdominal exerciser device
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
JP2002167389A (ja) * 2000-09-20 2002-06-11 Nikken Chem Co Ltd 新規チアゾールニ環化合物
JP2006524638A (ja) * 2003-04-30 2006-11-02 メルク フロスト カナダ リミテツド ８−（３−ビアリール）フェニルキノリン系ホスホジエステラーゼ−４阻害薬
MXPA05012377A (es) * 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
WO2011132048A1 (en) * 2010-04-19 2011-10-27 Glenmark Pharmaceutical S.A. Heteroaryl compounds as pde10a inhibitors
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
CN1823072A (zh) * 2003-05-15 2006-08-23 艾科尔公司 作为p38抑制剂的咪唑并噻唑和咪唑并噁唑衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cystic Fibrosis: A New Target for 4-Imidazo[2,1-b]thiazole-1,4-dihydropyridines;Roberta Budriesi et al.;《Journal of Medicinal Chemistry》;20110428;第54卷(第11期);3885-3894 *
Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the tyrosine kinases;Steve D. Fidanze et al.;《Bioorganic & Medicinal Chemistry Letters》;20100307;第20卷(第8期);2452-2455 *
Synthesis of imidazo[2,1-b]thiazoles linked to an unprotected carbohydrate moiety;Jos Sebastin Barradas et al.;《Carbohydrate Research》;20120421;第355卷;79-86 *

Also Published As

Publication number Publication date
BR112016011522B1 (pt) 2022-10-25
CA2930912C (en) 2021-10-26
BR112016011522A2 (https=) 2017-08-08
WO2015086504A1 (en) 2015-06-18
ES2743190T3 (es) 2020-02-18
RU2683940C1 (ru) 2019-04-03
US20160376290A1 (en) 2016-12-29
JP6483700B2 (ja) 2019-03-13
US10273247B2 (en) 2019-04-30
RU2016127226A (ru) 2018-01-23
TR201910983T4 (tr) 2019-08-21
EP3080133A1 (en) 2016-10-19
CN105814065A (zh) 2016-07-27
CA2930912A1 (en) 2015-06-18
JP2016539968A (ja) 2016-12-22
EP3080133B1 (en) 2019-07-10
GB201321731D0 (en) 2014-01-22

Similar Documents

Publication Publication Date Title
CN105814045B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN105814059B (zh) 作为tnf活性调节剂的咪唑并嘧啶衍生物
CN105814050B (zh) 用作tnf活性调节剂的吡唑并吡啶衍生物
CN105814060B (zh) 用作tnf活性调节剂的咪唑并三嗪衍生物
CN105814052B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN105829307B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
CN105814056B (zh) 用作tnf活性调节剂的嘌呤衍生物
CN105814022B (zh) 作为tnf活性调节剂的稠合的二环杂芳族衍生物
CN105814051B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
CN105814046B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN105814061B (zh) 作为tnf活性调节剂的咪唑并哒嗪衍生物
CN105814065B (zh) 用作tnf活性调节剂的咪唑并噻唑衍生物
CA2930142C (en) Tetrahydrobenzimidazole derivatives as modulators of tnf activity
CN105814058B (zh) 用作tnf活性调节剂的三唑并哒嗪衍生物
CN105814053B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN105814041A (zh) 用作tnf活性调节剂的苯并三唑衍生物
CN105814043A (zh) 用作tnf活性调节剂的三唑并吡啶衍生物
CN107787319A (zh) 作为tnf活性的调节剂的吲唑衍生物
CN105814044B (zh) 作为tnf活性调节剂的四氢咪唑并吡啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Brussels

Patentee after: UCB biopharmaceutical Co.,Ltd.

Address before: Brussels

Patentee before: UCB BIOPHARMA SPRL

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181123

CF01 Termination of patent right due to non-payment of annual fee